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Abstract 
The main objective of the study was to compare morphological and flow cytometric diagnosis in patients 
previously diagnosed with leukemia. The retrospective study was carried out at Moi Teaching and Referral 
Hospital and patient’s data for the period of July 2013 and June 2014 was used. After Institutional Research 
Ethics approval was granted. Consecutive sampling was done and information was extracted from patient’s 
files. Data for all who were previously diagnosed with leukemia through both morphology and 
immunophenotyping was recorded. The data was collected using a data collection form where socio-
demographic data, morphological and flow cytometry results were recorded. The findings were based on 33 
patients who underwent both flow cytometry and bone marrow morphology tests for diagnosis of leukemia 
between July 2013 and June 2014. The ages of the patients ranged from 3 to 76 years. The ratio of male to 
female was 1:1.1.  
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Using the Bone marrow morphology, 17 patients had AML and 15 had ALL, one case was inconclusive There 
were five categories for the flow cytometry. They comprised of B-ALL-6 cases, T-ALL-13 cases, AML-10 
cases, Biphynotypic-1 case and inconclusive-1case. There was concordance between the morphological and 
flow cytometry on 25 out of the 33 cases. As a conclusion we can say that at MTRH, Flow cytometry had a role 
to play to confirm a definite and a probable diagnosis of patients with acute leukemia.  
Keywords: Leukemia; Cytomorphology; Flow cytometry; AML; B-ALL; T-ALL. 
1. Introduction 
The bone marrow (BM) is a complex tissue containing cells of multiple hematopoietic cell lineages in all stages 
of development. Flow cytometric immunophenotyping evaluates the frequencies of the various leukocyte (sub) 
populations in BM and blood that then helps in the diagnosis of leukemia’s. 
Historically, leukemia has been classified initially into four groups based on a combination of clinical 
presentation and morphologic appearance of malignant cells: Acute lymphoblastic leukemia (ALL), acute 
myeloid leukemia (AML, also named acute non lymphocytic leukemia ANLL), chronic myelogenous leukemia 
(CML) and chronic lymphocytic leukemia (CLL). Subsequent research investigations and technological 
advances in the last twenty years, have evaluated the morphologic, immunologic, growth regulation, 
cytogenetic, and molecular abnormalities in leukemic cells, further establishing that leukemia is actually a much 
more heterogeneous group of disorders than initially suggested. In a study by Sengar et al, 100 untreated 
patients with AL were studied using morpho-cytochemistry and immunophenotyping through FCM, it was 
concluded that  FCM thus had a role to play in ALL patients to confirm a definite and a probable diagnosis, to 
define therapeutically and prognostically groups such as B and T lineage ALL and to distinguish AML – M0 
from ALL. While morpho-cytochemistry provides a first-line investigation of great therapeutic value, and more 
so in AML, it needs to be supplemented by flow cytometry, particularly in ALL [1].  
The use of flow cytometry provides an insight into differentiation pathways, maturation stages and abnormal 
features of these (sub) populations which are clinically relevant for the diagnosis of hematological 
malignancies. The presence and absence of antigens on or in the cell (sub) populations, a r e  recognized 
by various m o n o c l o n a l  a n t i b o d i e s  ( MAb) which gives characteristic immunostaining defining the 
cell lineages thus helping in making the diagnosis of Leukemias [2,3]. 
The consideration of which Mab’s for diagnosis is very important and a lot of researchers have addressed this 
problem. Morphological diagnosis alone for leukemia’s cannot diagnose leukemia’s correctly and cases can be 
missed out. At MTRH Flow Cytometric Immunophenotyping has been incorporated in  the diagnosis and further 
characterization of acute leukemia in addition to morphological diagnosis. Leukemia is the 6th among the top ten 
oncological disorders in the Western region of Kenya (Eldoret Cancer Registry 2005-2009 data) with a total of 
73 cases of acute leukemia. Among these leukemia’s 5.3% are lymphoid, 5.3% myeloid and 1.4% were 
unspecified. The flow cytometry immunophenotyping helps to differentiate the unspecified leukemia’s. In this 
study a four colour flow cytometric immunostaining combination was used to diagnose leukemia. 
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2. Materials and methods 
2.1 Study Area 
Moi Teaching and Referral Hospital hematology laboratory, AMPATH reference laboratories and Records 
department 
2.2 Study Design 
Retrospective study. 
2.3 Study population 
Files of patients diagnosed with leukemia 
2.4 Sampling Procedure 
File records and results for patients previously diagnosed to have leukemia on the basis of complete blood 
counts, peripheral blood films, bone marrow and flow cytometry findings were perused and data recorded in a 
data collection form. All files were sampled for the period of July 2013 to June 2014, those with complete 
records were included in the study. Those files with BMA morphological diagnosis but without flow results 
were not included in the study and vice versa. 
2.5 Cytomorphological classification of Acute Leukemia 
The original classification scheme proposed by the French-American-British (FAB) Cooperative Group divides 
AML into 7 subtypes (M0 to M7) and ALL into 3 subtypes (L1 to L3).More recently, an additional class AML 
M8 (acute basophilic leukemia) has been described .In this study the morphological diagnosis was put into only 
2 categories i.e ALL and  AML  
2.6 Immunophenotyping 
Equipment: Four colour computerized BD FACS caliber. The fluorochromes FITC, PE, PerCP, PerCP Cy5.5 
and APC were used. 
Samples: BMA ( 1-2mls) or Peripheral blood (4-7 mls) in EDTA tube ,processed within 24-48hrs. 
The following  panel of monoclonal antibodies were used depending on availability. 
Pan Leukocyte antigen: CD 45 is a pan leukocyte marker 
 B- cell– CD10, CD19, CD20, CD79a 
74 
 
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2015) Volume 13, No  1, pp 72-80 
 
T cell; CD3, CD4, CD7, CD8, cyt CD3, Tdt 
Myeloid; CD33, CD38, CD117, MPO.  
Immature cell antigens; CD34, and HLADR 
Erythroid marker: CD71 
Some combinations used were as follows:  
Tube1:CD 45 
Tube 2:CD19 and CD20 
Tube 3: CD33 and CD5 
Tube 4:HLADR and CD33 
Tube 5:cyt CD79a 
Tube 6: CD3 and CD4 
Tube 7:cyt CD3 
Tube 8: anti-MPO 
3. Results 
The findings that were used in this study were based on 33 samples for patients whose results showed both flow 
cytometry and morphological diagnosis between July 2013 and June 2014.  
 
Figure1: Age distribution 
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The age of the patients ranged from 3 to 76 years. Females constituted 53% and the rest were males. 
 
Figure 2: Bone Marrow Morphology diagnosis 
Using the Bone marrow morphology, diagnoses were only classified conclusively as AML or ALL with only 1 
having inconclusive results. 
 
Figure 3: Flow Cytometry diagnosis 
In Flow Cytometry the diagnoses were classified into 5 categories  
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Table 1: Comparison of flow Cytometry and bone marrow morphology tests using the morphology test as the 
Gold standard. Validity of the test (Cytometry) in diagnosing ALL 
  Morphology Test (gold standard)  
  +ve -ve Total  
Cytometry test 
+ve 12 6 18 
-ve 3 11 14 
 Total  15 17 32 
 
The ability of the Cytometry test to identify correctly those who have ALL (Sensitivity of cytometry test) was 
80%.  
The ability of the Cytometry test to identify correctly those who do not have ALL (Specificity of cytometry test) 
was 64.7%. 
The probability of a person having the ALL on BMA and Cytometry test showing positive results is 66.7% 
likewise the probability of a person not having the ALL and Cytometry test showing so is 78.6%. 
Table 2: Validity of the test (cytometry) in diagnosing AML 
  Morphology Test (gold standard)  
  +ve -ve Total  
Cytometry test 
+ve 7 2 9 
-ve 10 13 23 
 Total  17 15 32 
The ability of the Cytometry test to identify correctly those who have AML (Sensitivity of cytometry test)was 
41.2%. 
The ability of the Cytometry test to identify correctly those who do not have AML (Specificity of cytometry 
test) was 86.7%. 
The probability of a person having the AML on BMA and flow Cytometry test showing positive results is 
77.8% likewise the probability of a person not having the AML and Cytometry test showing so is 56.5%. 
Table 3 shows the results of patients who had discrepancies between the flow cytometry and morphological 
diagnosis. 
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Table 3: Comparison of morphological and Flow cytometry diagnosis on disagreeing results 
Serial 
number 
Clinical 
data 
Morphological  
diagnosis 
Flow cytometry diagnosis 
003 40yr M AML M5 CD45(dim)-95%,  CD33(95%),  CD38(86%), 
HLADR(92%), CytCD3(95%), MPO-4% -Reported as T-
ALL 
004 60yr F  
 
AML M5 CD 45(dim)-21%, cytCD7a-21%-Reported as B-ALL 
006 12yr M Inconclusive CD45(dim)-66%, CD38(51%),CD33(50%) HLADR(43%)-
Reported as AML 
015 36yr,F AML M2 CD45(bright)-30%, CD5(31%)-Inconclusive 
017 7 yr M 
 
ALL CD45dim)-73%, CD5(61%), cyt CD3(34%), 
MPO(41%),CD71(74%)-Reported as T-ALL 
025 24yr  M 
 
AML M1 CD45(dim)-82%, CD33(74%), HLADR(73%), 
cytCD3(93%)-Reported as T-ALL 
032 17yr  M 
 
ALL CD45 (bright)-28%, CD3(20%)-Inconclusive results 
033 5yr M 
 
AML(PBF),BMA 
Inadequate 
CD45(bright)-54%,CD45(dim)-22% CD19(24%), 
CD3(54%), CD5(52%),HLADR-35%, CD79a(23%)-
Reported as  T-ALL 
 
4. Discussions 
We analyzed 33 patients with complete records, who had bone aspirate done for diagnosis of acute leukemia and 
both morphological diagnosis and flow cytometry had been performed on their samples. The data showed that 
the age of the patients ranged from 3 to 76 years with an average of 22±20 years the paediatric patients were 18 
(50%) of the cases. The ratio of male to female was 1:1.1. 
In a study by S et al 260 cases were analysed for the study as the diagnostic workup was complete in these 
cases. Sixty-two patients belonged to the pediatric age group while there were 198 adults. There were 187 males 
and 73 females. This differed from our study which paedatric patients constituted 50% and male to female ratio 
was almost 1.1[6]. 
Using the Bone marrow morphology, diagnoses were only classified conclusively as AML 17(51%) or ALL 
15(45%) with only 1 having inconclusive results. 
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In Flow Cytometry the diagnoses were classified into 5 categories.B-ALL 9(27%), T-ALL 10 (30%), AML 
10(30%), biphenotypic-1(3%) and 2 inconclusive cases. 
In a study by Sengar et al, done on 100 untreated patients with Acute leukemia comparisons were done using 
morpho-cytochemistry and immunophenotyping through FCM. The findings showed 29 patients with acute 
myeloid leukemia (AML), 47 with B-acute lymphoblastic leukemia (ALL), 20 with T-acute lymphoblastic 
leukemia (ALL) and four with biphenotypic acute leukemia (BAL). Morpho-cytochemistry without FCM could 
provide definite diagnosis only in the AML cases. It failed to provide definite diagnosis in ALL patients. Over 
half (55%) of ALL patients were given the noncommittal label, AL. The remaining 45% patients were labeled a 
more definite, probable ALL [1]. 
This study differs from our study in that the patients with B-ALL were found to be almost double the number in 
comparison to those with T-ALL. In our study the number was 50/50.This study concluded that the flow 
cytometry was needed more for diagnosis of ALL  
In this study results were concordant in 25 cases, whereas in 8 cases the results were discordant comparison was 
done between BMA morphology and immunophenotyping only. Morphology was used as the gold standard to 
compare the 2 tests. The ability of the Cytometry test to identify correctly those who have ALL (Sensitivity of 
cytometry test) was 80%. The ability of the Cytometry test to identify correctly those who have AML 
(Sensitivity of cytometry test) was 41.2%. 
These findings were similar to a study by Beluakar et al whereby 50 cases of acute leukemia were analyzed and 
found concordance rate as high as 86% between morphologic/cytochemical diagnosis and flow cytometric 
diagnosis. Of these, complete concordance was seen in 58% of the cases and partial concordance was seen in 
22% of the cases. Non-concordance was seen in only 4% of those cases. In remaining 16% of the cases FCA 
helped in sub classifying the acute leukemia where morphology and cytochemistry had failed to do so [11]. For 
the 8 discordant cases, flowcytometry able to make a final diagnosis in2 cases, which lead to adaptation of 
treatment and finally complete remission. In the other 6 cases, the available markers were too limited to make a 
clear diagnosis. Especially in suspected biphenotypic cases, the flowcytometry could have been of extra value 
but was restricted by the available markers. There were also some inconclusive results because of too few events  
5. Conclusions  
 Flow cytometric immunophenotyping was found to be especially useful in the correct identification and 
diagnosis of acute myeloid and lymphoblastic leukemia and should be developed in terms of training more 
personnel and validating the test for commercial use. This study shows that flow is complementary to 
morphological diagnosis. There were challenges especially where sample collection was not properly done or 
had few cells, this led to inconclusive results. 
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